

## TZIELD (TEPLIZUMAB) INFUSION ORDERS

**P:** 877.365.5566 | **F:** 855.889.2946

PATIENT INFORMATION:	Fax completed form, insuran	ce information, and clinical documentation to 855.889.2946	
		DOB: Phone:	
Patient Status: ☐ New to Therapy	☐ Continuing Therapy	Next Treatment Date:	
MEDICAL INFORMATION			
<b>Diagnosis:</b> ☐ Type 1 diabetes mellitus with unspecified complications (ICD-10: E10.8)			
☐ Type 1 diabetes mellitus without complications (ICD-10: E10.9)			
☐ Other: ICD-10 code:			
Patient Weight: lbs. (red	quired) Patient Height:	inches (required)	
Allergies:			
THERAPY ORDER			
☐ Infuse Tzield IV daily for 14 days ac	cording to the following do	osing regimen:	
<ul> <li>Day 1: 65 mcg/m²</li> </ul>	<ul> <li>Day 3: 250 mcg/m²</li> </ul>	<ul> <li>Day 5 through 14: 1,030 mcg/m²</li> </ul>	
<ul> <li>Day 2: 125 mcg/m²</li> </ul>	<ul> <li>Day 4: 500 mcg/m²</li> </ul>		
Patients should be pre-medicated w	ith ADAD or NSAID antibio	stamine, and/or an anti-emetic for 1st 5 doses	
Pre-medication orders:	ILITAPAP OF NSAID, BITUITIS	starrine, and/or arranti-errietic for ist 3 doses	
☐ Acetaminophen mg PO	□ Ibuprofen mo	g PO 🔲 Toradol 30mg IV	
☐ Diphenhydramine 25 mg PO			
☐ Zofran mg IV			
		o all doses  Other:	
	J doses offig	our doses ourer.	
Lab orders:  ☐ Baseline CBC w/diff & LFTs (required)			
Baseline hold parameters: Lymphocyte count <1,000/mcL, Hgb <10g/dL, Platelets <150,000/mcL,			
ANC <1,500/mcL, ALT/AST > 2x ULN, or bilirubin > 1.5x ULN			
☐ Repeat CBC w/diff & LFTs every day(s)			
Notify physican for abnormal labs. Discontinue treatment for AST/ALT > 5x ULN or bilirubin > 3x ULN			
Discontinue treatment for prolonged lymphopenia (<500/mcL) lasting 1 week or longer			
Required labs to be drawn by: 🗆 Paragon 🗀 Referring physician			
Other orders:			
Home biologic IV Ana-kit (adult), dis	spansa par protocol:		
• EpiPen 0.3mg IM (2-pack) or			
<ul> <li>Diphenhydramine 50mg IV an</li> </ul>			
Normal Saline 1000mL			
PROVIDER INFORMATION	vision Demonstrative the constraint in the constraint		
agent in dealing with medical and prescription insurance con	mpanies, and to select the preferred site of	oloyees to serve as your prior authorization and specialty pharmacy designated care for the patient.	
Provider NDI:	Signature:	Date: Contact Person:	
☐ Opt out of Paragon selecting site	of care (if checked, please	e list site of care):	
PREFERRED LOCATION			
		وَيُهُونِ	
City: State	2:	View our locations here:	

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





## COMPREHENSIVE SUPPORT FOR TZIELD THERAPY

PATIENT INFORMATION:			
Patient Name: DOB:			
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE	E APPROVAL		
☐ Include signed and completed order (MD/prescriber to complete page 1)			
☐ Include patient demographic information and insurance information			
☐ Include patient's medication list			
$\hfill\square$ Supporting clinical notes (H&P) to support primary diagnosis - Including:			
$\square$ Does the patient have a at least two positive pancreatic islet cell autoa	intibodies?		
☐ Yes ☐ No If yes, please indicate:			
$\square$ Does the patient have dysglycemia without overt hyperglycemia? $\square$ Y	es □ No		
☐ Patient does not have a clinical history to suggest type 2 diabetes			
☐ Patient does not have an acute infection with Epstein-Barr Virus or Cy	tomegalovirus		
☐ Supporting labs/tests			
☐ Oral glucose tolerance test (if available)			
☐ Lab results indicating pancreatic islet cell autoantibodies			
Other medical necessity:			
REQUIRED PRE-SCREENING			
☐ Baseline CBC w/differential & LFTs - attach results			
☐ Pancreatic islet cell autoantibodies			
☐ Documentation of dysglycemia without overt hyperglycemia			

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance